A previous study demonstrated that the initiation and progression of pulmonary fibrosis was prevented by the administration of rapamycin, an mTOR inhibitor, to a transgenic mouse with pulmonary fibrosis induced by lung-specific expression of the EGFR ligand, transforming growth factor (TGF)-α [3]. Here, EGFR is linked to pulmonary fibrosis.